Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry

太龙药业最新公告:拟在云南设立全资子公司太龙本草
The latest announcement of Tai long Pharmaceutical Co., Ltd.: plans to set up a wholly-owned subsidiary Tai long Materia Medica in Yunnan

證券之星 ·  {{timeTz}}

太龙药业公告,公司拟以货币资金出资5000万元,在云南设立全资子公司太龙本草。

Tai long Pharmaceutical announced that the company intends to contribute 50 million yuan with monetary funds to set up a wholly owned subsidiary Tai long Materia Medica in Yunnan.

公司董事长为李景亮。李景亮先生:1969年1月出生,硕士学历,曾任本公司总经理、本公司副董事长、众生集团董事长。现任本公司董事长。

The chairman of the company is Li Jingliang. Mr. Li Jingliang: born in January 1969 with a master's degree, he once served as the general manager of the company, vice chairman of the company and chairman of Zhongsheng Group. He is currently the chairman of the company.

本文由证券之星数据中心根据公开数据汇总整理,不构成投资意见或建议,如有问题,请联系我们。

This article is compiled by the Securities Star data Center according to the public data and does not constitute investment opinions or suggestions. If you have any questions, please contact us.

This page is machine-translated. Moomoo tries to improve but do not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites https://www.futuau.com and https://www.moomoo.com/au. Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.